Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

BioVaxys Technology Corp. C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Latest News

BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow...


BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT


BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of...


BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND ANNOUNCES DEBT SETTLEMENT...


BIOVAXYS ANNOUNCES REPRICING OF PRIVATE PLACEMENT OFFERING


BioVaxys Shares New Data on its DPX(TM) Immune Educating Platform at Personalized Cancer Vaccine...


BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY


BioVaxys and SpayVac expand vaccine production in Madison


BioVaxys to Participate in the US Government Biomedical Advanced Research and Development...


BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based...


BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024


How BioVaxys' DPX platform creates anti-cancer immune response


BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor


BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT


BIOVAXYS ANNOUNCES CLOSING OF FOURTH TRANCHE OF PRIVATE PLACEMENT